Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Hepatitis C

  Free Subscription


Articles published in Gut

Retrieve available abstracts of 40 articles:
HTML format



Single Articles


    April 2021
  1. PHAM LV, Pedersen MS, Fahnoe U, Fernandez-Antunez C, et al
    HCV genome-wide analysis for development of efficient culture systems and unravelling of antiviral resistance in genotype 4.
    Gut. 2021 Apr 8. pii: gutjnl-2020-323585. doi: 10.1136/gutjnl-2020-323585.
    PubMed     Abstract available


    January 2021
  2. BUKH J
    Vaccines against hepatitis C: a travel into neutralisation space.
    Gut. 2021 Jan 25. pii: gutjnl-2020-323377. doi: 10.1136/gutjnl-2020-323377.
    PubMed    


  3. LIU CH, Chen CY, Su WW, Tseng KC, et al
    Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment.
    Gut. 2021 Jan 6. pii: gutjnl-2020-323569. doi: 10.1136/gutjnl-2020-323569.
    PubMed     Abstract available


    December 2020
  4. BANKWITZ D, Bahai A, Labuhn M, Doepke M, et al
    Hepatitis C reference viruses highlight potent antibody responses and diverse viral functional interactions with neutralising antibodies.
    Gut. 2020 Dec 15. pii: gutjnl-2020-321190. doi: 10.1136/gutjnl-2020-321190.
    PubMed     Abstract available


  5. YU ML, Huang CF, Wei YJ, Lin WY, et al
    Establishment of an outreach, grouping healthcare system to achieve microelimination of HCV for uremic patients in haemodialysis centres (ERASE-C).
    Gut. 2020 Dec 10. pii: gutjnl-2020-323277. doi: 10.1136/gutjnl-2020-323277.
    PubMed     Abstract available


    October 2020
  6. CASTRY M, Cousien A, Supervie V, Velter A, et al
    Impact of test-and-treat and risk reduction strategies on HCV transmission among MSM living with HIV in France: a modelling approach.
    Gut. 2020 Oct 27. pii: gutjnl-2020-321744. doi: 10.1136/gutjnl-2020-321744.
    PubMed     Abstract available


    June 2020
  7. ZOLDAN K, Hofmann M
    B protected: from vertical HCV transmission?
    Gut. 2020 Jun 30. pii: gutjnl-2020-321364. doi: 10.1136/gutjnl-2020-321364.
    PubMed    


    April 2020
  8. DE JONG YP, Liang TJ
    Stem cell-derived HCV infection systems illustrate the bright future of human hepatocyte research.
    Gut. 2020 Apr 29. pii: gutjnl-2020-321216. doi: 10.1136/gutjnl-2020-321216.
    PubMed    


  9. LUTCKII A, Strunz B, Zhirkov A, Filipovich O, et al
    Evidence for B cell maturation but not trained immunity in uninfected infants exposed to hepatitis C virus.
    Gut. 2020 Apr 27. pii: gutjnl-2019-320269. doi: 10.1136/gutjnl-2019-320269.
    PubMed     Abstract available


    March 2020
  10. HUTCHINSON SJ, Valerio H, McDonald SA, Yeung A, et al
    Population impact of direct-acting antiviral treatment on new presentations of hepatitis C-related decompensated cirrhosis: a national record-linkage study.
    Gut. 2020 Mar 26. pii: gutjnl-2019-320007. doi: 10.1136/gutjnl-2019-320007.
    PubMed     Abstract available


  11. YOUNOSSI ZM, Stepanova M, Younossi Y, Golabi P, et al
    Epidemiology of chronic liver diseases in the USA in the past three decades.
    Gut. 2020;69:564-568.
    PubMed     Abstract available


    February 2020
  12. CARPENTIER A, Sheldon J, Vondran FWR, Brown RJ, et al
    Efficient acute and chronic infection of stem cell-derived hepatocytes by hepatitis C virus.
    Gut. 2020 Feb 29. pii: gutjnl-2019-319354. doi: 10.1136/gutjnl-2019-319354.
    PubMed     Abstract available


    May 2019
  13. HERZOG K, Bandiera S, Pernot S, Fauvelle C, et al
    Functional microRNA screen uncovers O-linked N-acetylglucosamine transferase as a host factor modulating hepatitis C virus morphogenesis and infectivity.
    Gut. 2019 May 10. pii: gutjnl-2018-317423. doi: 10.1136/gutjnl-2018-317423.
    PubMed     Abstract available


    September 2018
  14. LLIBRE A, Shimakawa Y, Duffy D
    Potential utility of the Genedrive point-of-care test for HCV RNA detection.
    Gut. 2018 Sep 22. pii: gutjnl-2018-317218. doi: 10.1136/gutjnl-2018-317218.
    PubMed    


    June 2018
  15. LEMOINE M, Tillmann HL
    What is required from HCV point-of-care tests to reduce the burden of hepatitis C infection? 'Development and clinical validation of the genedrive point-of-care test for qualitative detection of hepatitis C virus'.
    Gut. 2018 Jun 29. pii: gutjnl-2018-316438. doi: 10.1136/gutjnl-2018-316438.
    PubMed    


  16. NEGRO F
    Expanded benefits of curing the extrahepatic manifestations of HCV infection.
    Gut. 2018 Jun 5. pii: gutjnl-2018-316578. doi: 10.1136/gutjnl-2018-316578.
    PubMed    


    April 2018
  17. CACOUB P, Desbois AC, Comarmond C, Saadoun D, et al
    Impact of sustained virological response on the extrahepatic manifestations of chronic hepatitis C: a meta-analysis.
    Gut. 2018 Apr 27. pii: gutjnl-2018-316234. doi: 10.1136/gutjnl-2018-316234.
    PubMed     Abstract available


  18. SHIHA G, Esmat G, Hassany M, Soliman R, et al
    Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt.
    Gut. 2018 Apr 17. pii: gutjnl-2017-315906. doi: 10.1136/gutjnl-2017-315906.
    PubMed     Abstract available


  19. LLIBRE A, Shimakawa Y, Mottez E, Ainsworth S, et al
    Development and clinical validation of the Genedrive point-of-care test for qualitative detection of hepatitis C virus.
    Gut. 2018 Apr 3. pii: gutjnl-2017-315783. doi: 10.1136/gutjnl-2017-315783.
    PubMed     Abstract available


    March 2018
  20. SAMSON A, Bentham MJ, Scott K, Nuovo G, et al
    Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer.
    Gut. 2018;67:562-573.
    PubMed     Abstract available


    January 2018
  21. CHEN CJ
    Global elimination of viral hepatitis and hepatocellular carcinoma: opportunities and challenges.
    Gut. 2018 Jan 24. pii: gutjnl-2017-315407. doi: 10.1136/gutjnl-2017-315407.
    PubMed    


    November 2017
  22. WANG X, Yan Y, Gan T, Yang X, et al
    A trivalent HCV vaccine elicits broad and synergistic polyclonal antibody response in mice and rhesus monkey.
    Gut. 2017 Nov 27. pii: gutjnl-2017-314870. doi: 10.1136/gutjnl-2017-314870.
    PubMed     Abstract available


    July 2017
  23. PETTA S, Craxi A
    Can we prevent and modify cardiometabolic disorders by controlling HCV infection?
    Gut. 2017 Jul 13. pii: gutjnl-2017-314505. doi: 10.1136/gutjnl-2017-314505.
    PubMed    


    June 2017
  24. LEVANDER S, Holmstrom F, Frelin L, Ahlen G, et al
    Immune-mediated effects targeting hepatitis C virus in a syngeneic replicon cell transplantation mouse model.
    Gut. 2017 Jun 23. pii: gutjnl-2016-313579. doi: 10.1136/gutjnl-2016-313579.
    PubMed     Abstract available


  25. MAHALE P, Engels EA, Li R, Torres HA, et al
    The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection.
    Gut. 2017 Jun 20. pii: gutjnl-2017-313983. doi: 10.1136/gutjnl-2017-313983.
    PubMed     Abstract available


  26. SUN HY, Cheng PN, Tseng CY, Tsai WJ, et al
    Favouring modulation of circulating lipoproteins and lipid loading capacity by direct antiviral agents grazoprevir/elbasvir or ledipasvir/sofosbuvir treatment against chronic HCV infection.
    Gut. 2017 Jun 14. pii: gutjnl-2017-313832. doi: 10.1136/gutjnl-2017-313832.
    PubMed     Abstract available


  27. ARRIAZU E, Ge X, Leung TM, Magdaleno F, et al
    Signalling via the osteopontin and high mobility group box-1 axis drives the fibrogenic response to liver injury.
    Gut. 2017;66:1123-1137.
    PubMed     Abstract available


    March 2017
  28. COLPITTS CC, Tawar RG, Mailly L, Thumann C, et al
    Humanisation of a claudin-1-specific monoclonal antibody for clinical prevention and cure of HCV infection without escape.
    Gut. 2017 Mar 30. pii: gutjnl-2016-312577. doi: 10.1136/gutjnl-2016-312577.
    PubMed     Abstract available


  29. LAURAIN A, Kramer L, Sultanik P, Vallet-Pichard A, et al
    Mortality associated with the treatment of HCV with direct-acting antivirals.
    Gut. 2017 Mar 23. pii: gutjnl-2017-313869. doi: 10.1136/gutjnl-2017-313869.
    PubMed    


    February 2017
  30. VAN RENNE N, Roca Suarez AA, Duong FH, Gondeau C, et al
    miR-135a-5p-mediated downregulation of protein tyrosine phosphatase receptor delta is a candidate driver of HCV-associated hepatocarcinogenesis.
    Gut. 2017 Feb 3. pii: gutjnl-2016-312270. doi: 10.1136/gutjnl-2016-312270.
    PubMed     Abstract available


    January 2017
  31. MENARD A, Aherfi S, Mokhtari S, Dhiver C, et al
    Toward chronic hepatitis C eradication in HIV-positive patients, including those cirrhotic and infected with genotype 3 viruses.
    Gut. 2017 Jan 10. pii: gutjnl-2016-313431. doi: 10.1136/gutjnl-2016-313431.
    PubMed    


  32. BUDKOWSKA A
    Intriguing structure of the HCV particle.
    Gut. 2017 Jan 5. pii: gutjnl-2016-313184. doi: 10.1136/gutjnl-2016-313184.
    PubMed    


    December 2016

  33. Erratum: Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort.
    Gut. 2016;65:2060.
    PubMed    


    November 2016
  34. ROINGEARD P, Dreneau J, Meunier JC
    Unravelling the multiple roles of apolipoprotein E in the hepatitis C virus life cycle.
    Gut. 2016 Nov 3. pii: gutjnl-2016-312774. doi: 10.1136/gutjnl-2016-312774.
    PubMed    


    October 2016
  35. YOKOKAWA H, Higashino A, Suzuki S, Moriyama M, et al
    Induction of humoural and cellular immunity by immunisation with HCV particle vaccine in a non-human primate model.
    Gut. 2016 Oct 26. pii: gutjnl-2016-312208. doi: 10.1136/gutjnl-2016-312208.
    PubMed     Abstract available


  36. PIVER E, Boyer A, Gaillard J, Bull A, et al
    Ultrastructural organisation of HCV from the bloodstream of infected patients revealed by electron microscopy after specific immunocapture.
    Gut. 2016 Oct 11. pii: gutjnl-2016-311726. doi: 10.1136/gutjnl-2016-311726.
    PubMed     Abstract available


    September 2016
  37. CROUCHET E, Lefevre M, Verrier ER, Oudot MA, et al
    Extracellular lipid-free apolipoprotein E inhibits HCV replication and induces ABCG1-dependent cholesterol efflux.
    Gut. 2016 Sep 8. pii: gutjnl-2015-311289. doi: 10.1136/gutjnl-2015-311289.
    PubMed     Abstract available


    June 2016
  38. GOUTTENOIRE J, Szkolnicka D, Moradpour D
    Treatment of chronic hepatitis E with ribavirin: lessons from deep sequencing.
    Gut. 2016 Jun 22. pii: gutjnl-2016-312040. doi: 10.1136/gutjnl-2016-312040.
    PubMed    


    February 2016
  39. JAMIL KM, Hydes TJ, Cheent KS, Cassidy SA, et al
    STAT4-associated natural killer cell tolerance following liver transplantation.
    Gut. 2016 Feb 17. pii: gutjnl-2015-309395. doi: 10.1136/gutjnl-2015-309395.
    PubMed     Abstract available


    October 2015
  40. NAHON P, Lescat M, Layese R, Bourcier V, et al
    Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir prospective cohort).
    Gut. 2015 Oct 28. pii: gutjnl-2015-310275. doi: 10.1136/gutjnl-2015-310275.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis C is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: